Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni and Epclusa in HCV-associated Indolent B-cell Lymphoma
NCT02836925Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2016
- Primary completion
- Feb 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ledipasvir, velpatasvir in hepatitis C (HCV), indolent B-cell lymphoma, sponsored by Fondazione Italiana Linfomi. Started Mar 2016; status: completed.
02
Drugs
ledipasvirvelpatasvir
03
Conditions
hepatitis C (HCV)indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT02836925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836925.